Search Results 11-20 of 1232 for ���������������������katalk:PC53���200%������ ��������� ������ ���������������������������������

  1. Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone - Mayo Clinic

    Dexamethasone is a drug used in chemotherapy that may cause tumor cells to die. Zoledronic acid may prevent bone fractures and reduce bone pain, and may also ...

  2. A Study of Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M) - Mayo Clinic

    The purpose of this study is to evaluate the investigational drug PledOx in the prevention of chronic chemotherapy induced peripheral neuropathy (CIPN) induced ...

  3. Leukemia Clinical Trials

    ... TP53 mutant acute myeloid leukemia (AML) who are appropriate for non-intensive therapy as measured by overall survival (OS). A Study of Tretinoin and ...

  4. https://www.mayoclinic.org/spanish_procedure_concepts.xml

    ... 53:37-06:00</lastmod><xhtml:link rel="alternate" hreflang="ar" href="https://www.mayoclinic.org/ar/tests-procedures/aortic-root-surgery/about/pac-20383396 ...

  5. Mayo Clinic Comprehensive Cancer Center — Research

    The purpose of the study is to explore the safety and efficacy of CLT-008 as an extra supportive care measure during induction chemotherapy for patients with ...

  6. Study of Oral LOXO-338 in Patients With Advanced Blood Cancers - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  7. Cancer risk: What the numbers mean - Mayo Clinic

    A relative risk of 100% means your risk is twice as high as that of someone without that risk factor. A 200% relative risk means that you are three times as ...

  8. Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer - Mayo Clinic

    The investigators want to find out what effects, good and/or bad, CAMP has on patients and their metastatic castration-resistant prostate cancer. Participation ...

  9. A Study to Evaluate DS-1062a Combined with Pembrolizumab in Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations - Mayo Clinic

    for locally advanced or metastatic NSCLC. - Dose expansion (cohorts with 4.0 mg/kg or 6.0 mg/kg Dato-DXd in combination with 200 mg fixed dose of ...

  10. An Extension Study MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue - Mayo Clinic

    Sponsor Protocol Number: NBI-PC-002.1. About this study. To determine the efficacy of using MRI/US fusion imaging technology to direct focal ablation of ...